First Affiliated Hospital of Zhejiang University: Leukemia, Myeloid, Acute trials

The registry lists 12 Leukemia, Myeloid, Acute studies with First Affiliated Hospital of Zhejiang University as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 2Phase 2 8Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651176Phase 2/3
• Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651163Phase 2/3
• Romiplostim N01 for Platelet Recovery After Haploidentical HSCTRecruitingNCT07321626Phase 1
• Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AMLRecruitingNCT07259707Phase 2
• A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT07198867Phase 1
• Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)RecruitingNCT07183878Not applicable
• Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AMLRecruitingNCT07172204Phase 2
• Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.Not yet recruitingNCT06786299Early Phase 1
• Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AMLRecruitingNCT06621212Phase 2
• Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
• Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
• Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedNCT05906914Phase 2